Expression and prognostic value of E2F3 transcription factor in non‑small cell lung cancer

Wu,Lei; Wan,Shan; Li,Jinfan; Xu,Yiying; Lou,Xiaoli; Sun,Maomin; Wang,Shouli

doi:10.3892/ol.2021.12672

Expression and prognostic value of E2F3 transcription factor in non‑small cell lung cancer

Authors:
- Lei Wu
- Shan Wan
- Jinfan Li
- Yiying Xu
- Xiaoli Lou
- Maomin Sun
- Shouli Wang
View Affiliations

Affiliations: Department of Pathology, School of Biology and Basic Medical Sciences, Soochow University, Suzhou, Jiangsu 215123, P.R. China, Department of Pathology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China, Laboratory Animal Research Center, Soochow University School of Medicine, Suzhou, Jiangsu 215123, P.R. China
Published online on: March 22, 2021 https://doi.org/10.3892/ol.2021.12672
Article Number: 411
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

E2F transcription factor 3 (E2F3) plays a vital role in the development of various types of cancer. To verify whether E2F3 is a suitable biomarker for the prognosis of lung cancer, bioinformatics analysis was performed to determine the differential expression level of E2F3 in lung cancer and the surrounding non‑tumor tissues, and the results were confirmed in a NSCLC cell line and a tissue microarray (TMA). The relevance of E2F3 in non‑small cell lung cancer (NSCLC) was investigated in 19 studies from the Oncomine database and confirmed in The Cancer Genome Atlas database. In the lung cancer cell line A549, the inhibition of E2F3 mRNA expression level led to decreased tumor cell viability and cell migration, which was determined by a Cell Counting Kit‑8 and wound healing assays, respectively. Immunohistochemistry analyses of E2F3, Bcl‑2, Bax and caspase‑3 were performed in the NSCLC TMA (n=50). The assessment of TMA detected the increase of E2F3 protein expression level in the tumor tissues, as compared with that in the non‑tumor tissues, which was also correlated with the increase in expression of Bcl‑2 in tumors. Analysis of the clinical data from patients with NSCLC revealed that the overexpression of E2F3 was associated with early lymphatic spreading, and poor patient survival time. The OncomiR website was used to predict the E2F3 upstream microRNAs and determine their prognostic value in patients with NSCLC. The results from the present study revealed that E2F3 was overexpressed at both the transcriptional and translational levels in NSCLC tissues, as compared with that in non‑tumor tissues. The overexpression of E2F3 was associated with the upregulation of the anti‑apoptotic factor, Bcl‑2, which may contribute to uncontrolled tumor growth. Thus, E2F3 was shown to have important oncogenic properties in the development of NSCLC, and it may become a potential biomarker for patients with NSCLC.

View Figures

View References

1	Chen WQ, Li H, Sun KX, Zheng RS, Zhang SW, Zeng HM, Zou XN, Gu XY and He J: Report of cancer incidence and mortality in China, 2014. Zhonghua Zhong Liu Za Zhi. 40:5–13. 2018.(In Chinese). PubMed/NCBI
2	Oliver TG, Patel J and Akerley W: Squamous non-small cell lung cancer as a distinct clinical entity. Am J Clin Oncol. 38:220–226. 2015. View Article : Google Scholar : PubMed/NCBI
3	Osmani L, Askin F, Gabrielson E and Li QK: Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin Cancer Biol. 52:103–109. 2018. View Article : Google Scholar : PubMed/NCBI
4	Cancer Genome Atlas Research Network, . Comprehensive molecular profiling of lung adenocarcinoma. Nature. 511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
5	Segundo-Val IS and Sanz-Lozano CS: Introduction to the gene expression analysis. Methods Mol Biol. 1434:29–43. 2016. View Article : Google Scholar : PubMed/NCBI
6	Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM: ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
7	Gyorffy B, Surowiak P, Budczies J and Lánczky A: Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar : PubMed/NCBI
8	Lánczky A, Nagy A, Bottai G, Munkácsy G, Szabó A, Santarpia L and Győrffy B: MiRpower: A web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. 160:439–446. 2016. View Article : Google Scholar : PubMed/NCBI
9	Zhu Y, Peng Q, Lin Y, Zou L, Shen P, Chen F, Min M, Shen L, Chen J and Shen B: Identification of biomarker microRNAs for predicting the response of colorectal cancer to neoadjuvant chemoradiotherapy based on microRNA regulatory network. Oncotarget. 8:2233–2248. 2017. View Article : Google Scholar : PubMed/NCBI
10	Sarver AL, Sarver AE, Yuan C and Subramanian S: OMCD: OncomiR cancer database. BMC Cancer. 18:12232018. View Article : Google Scholar : PubMed/NCBI
11	Zhan L, Zhang Y, Wang W, Song E, Fan Y and Wei B: E2F1: A promising regulator in ovarian carcinoma. Tumour Biol. 37:2823–2831. 2016. View Article : Google Scholar : PubMed/NCBI
12	Park SA, Platt J, Lee JW, López-Giráldez F, Herbst RS and Koo JS: E2F8 as a novel therapeutic target for lung cancer. J Natl Cancer Inst. 107:1512015. View Article : Google Scholar
13	Kurtyka CA, Chen L and Cress WD: E2F inhibition synergizes with paclitaxel in lung cancer cell lines. PLoS One. 9:e963572014. View Article : Google Scholar : PubMed/NCBI
14	Rotgers E, Rivero-Müller A, Nurmio M, Parvinen M, Guillou F, Huhtaniemi I, Kotaja N, Bourguiba-Hachemi S and Toppari J: Retinoblastoma protein (RB) interacts with E2F3 to control terminal differentiation of sertoli cells. Cell Death Dis. 5:e12742014. View Article : Google Scholar : PubMed/NCBI
15	Danielian PS, Friesenhahn LB, Faust AM, West JC, Caron AM, Bronson RT and Lees JA: E2f3a and E2f3b make overlapping but different contributions to total E2f3 activity. Oncogene. 27:6561–6570. 2008. View Article : Google Scholar : PubMed/NCBI
16	Lou X, Fu J, Zhao X, Zhuansun X, Rong C, Sun M, Niu H, Wu L, Zhang Y, An L, et al: MiR-7e-5p downregulation promotes transformation of low-grade follicular lymphoma to aggressive lymphoma by modulating an immunosuppressive stroma through the upregulation of FasL in M1 macrophages. J Exp Clin Cancer Res. 39:2372020. View Article : Google Scholar : PubMed/NCBI
17	Montojo J, Zuberi K, Rodriguez H, Bader GD and Morris Q: GeneMANIA: Fast gene network construction and function prediction for cytoscape. F1000Res. 3:1532014. View Article : Google Scholar : PubMed/NCBI
18	Zhang C, Liu J, Jin N, Zhang G, Xi Y and Liu H: SiRNA targeting mTOR effectively prevents the proliferation and migration of human lens epithelial cells. PLoS One. 11:e01673492016. View Article : Google Scholar : PubMed/NCBI
19	Collins TJ: ImageJ for microscopy. Biotechniques. 43:25–30. 2007. View Article : Google Scholar : PubMed/NCBI
20	Meyers DE, Bryan PM, Banerji S and Morris DG: Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer. Curr Oncol. 25:e324–e334. 2018. View Article : Google Scholar : PubMed/NCBI
21	Guinde J, Frankel D, Perrin S, Delecourt V, Lévy N, Barlesi F, Astoul P, Roll P and Kaspi E: Lamins in lung cancer: Biomarkers and key factors for disease progression through miR-9 regulation? Cells. 7:782018. View Article : Google Scholar
22	Suzuki T, Yasui W, Yokozaki H, Naka K, Ishikawa T and Tahara E: Expression of the E2F family in human gastrointestinal carcinomas. Int J Cancer. 81:535–538. 1999. View Article : Google Scholar : PubMed/NCBI
23	Oliveira A, Beyer G, Chugh R, Skube SJ, Majumder K, Banerjee S, Sangwan V, Li L, Dawra R, Subramanian S, et al: Triptolide abrogates growth of colon cancer and induces cell cycle arrest by inhibiting transcriptional activation of E2F. Lab Invest. 95:648–659. 2015. View Article : Google Scholar : PubMed/NCBI
24	Salon C, Merdzhanova G, Brambilla C, Brambilla E, Gazzeri S and Eymin B: E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors. Oncogene. 26:6927–6936. 2007. View Article : Google Scholar : PubMed/NCBI
25	Li X, Li H, Zhang R and Liu J and Liu J: MicroRNA-449a inhibits proliferation and induces apoptosis by directly repressing E2F3 in gastric cancer. Cell Physiol Biochem. 35:2033–2042. 2015. View Article : Google Scholar : PubMed/NCBI
26	Sherlock G and Ball CA: Storage and retrieval of microarray data and open source microarray database software. Mol Biotechnol. 30:239–251. 2005. View Article : Google Scholar : PubMed/NCBI
27	Frank DK, Liu TJ, Frederick MJ and Clayman GL: Combination E2F-1 and p53 gene transfer does not enhance growth inhibition in human squamous cell carcinoma of the head and neck. Clin Cancer Res. 4:2265–2272. 1998.PubMed/NCBI
28	Zhou X, Ji G, Ke X, Gu H, Jin W and Zhang G: MiR-141 inhibits gastric cancer proliferation by interacting with long noncoding RNA MEG3 and down-regulating E2F3 expression. Dig Dis Sci. 60:3271–3282. 2015. View Article : Google Scholar : PubMed/NCBI
29	Xue J, Niu YF, Huang J, Peng G, Wang LX, Yang YH and Li YQ: MiR-141 suppresses the growth and metastasis of HCC cells by targeting E2F3. Tumour Biol. 35:12103–12107. 2014. View Article : Google Scholar : PubMed/NCBI
30	Naeini MM, Tavassoli M and Ghaedi K: Systematic bioinformatic approaches reveal novel gene expression signatures associated with acquired resistance to EGFR targeted therapy in lung cancer. Gene. 667:62–69. 2018. View Article : Google Scholar : PubMed/NCBI